JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 4 Publications

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell M13KVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OzJ|NjFOwG0> NGLmO4RUSU6JRWK=
H4 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MljsTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwME[3NFch|ryP NITTTItUSU6JRWK=
KGN cell NHLQSppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV6wR3hLUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN MkHWV2FPT0WU
786-0 cell Ml22S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn[zTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|I6QDlizszN NVrmO3ljW0GQR1XS
769-P cell MoG5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;EXo9KdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OjJ{NDFOwG0> MVrTRW5ITVJ?
K5 cell NGXxXlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDKTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMEG2NlQh|ryP MX3TRW5ITVJ?
MLMA cell NILBRpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYfsNnZyUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB|MkG3JO69VQ>? NGPzcmFUSU6JRWK=
MLMA cell M4rYUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkK4O|A{KM7:TR?= NWPzbZQ4W0GQR1XS
EW-7 cell NIX0XWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4S3PWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|I3QTVizszN MX3TRW5ITVJ?
SW1088 cell NHvMZmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV72OZdXUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjhyNkWxJO69VQ>? NUHjTlVrW0GQR1XS
MC-IXC cell Mnq5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFc4QTJizszN NGjlNFNUSU6JRWK=
NCI-H2052 cell M2[1Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODhzNUeg{txO NUHafJdZW0GQR1XS
IGR-1 cell MofES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XxdGlvcGmkaYTpc44hd2ZiaIXtZY4hUUeULUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlEzODJ6IN88US=> NVyxb3I5W0GQR1XS
DSH1 cell NFrRZppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkK0Nlk3KM7:TR?= M1POeXNCVkeHUh?=
PA-1 cell MnHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLjeWNYUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{ODB3Od88US=> NV\QflJvW0GQR1XS
SK-MEL-3 cell M4\ESGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\ncY1KdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5|MUKwO{DPxE1? NXfUS2E2W0GQR1XS
SW900 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2DURWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> M3jxZ3NCVkeHUh?=
CAKI-1 cell MoHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI4OzhizszN Ml\FV2FPT0WU
ES1 cell M1nrT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIPr[WxKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI5QTdizszN NGDWRWdUSU6JRWK=
SK-N-DZ cell NWrkbnZyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=> MlzHV2FPT0WU
RH-1 cell Mm\6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DnVmlvcGmkaYTpc44hd2ZiaIXtZY4hWkhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlg1PjNizszN NGrjU|VUSU6JRWK=
ES8 cell MkfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjsTYZKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlk4ODJizszN MWfTRW5ITVJ?
NEC8 cell MnPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lke2PVgzKM7:TR?= NHzVdG1USU6JRWK=
LNCaP-Clone-FGC cell M3XFZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFM2OzZizszN M{PBV3NCVkeHUh?=
HCE-4 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLiUoRyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0> NEfu[G1USU6JRWK=
U-118-MG cell Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NY\FR296UW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMEGwOlYh|ryP NIDl[GVUSU6JRWK=
GI-ME-N cell Mlz1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;SNII3UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1? NXm0WmVTW0GQR1XS
LB1047-RCC cell M4jSbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYf0SZFVUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOlE1OyEQvF2= NXvQVG9DW0GQR1XS
HT-1080 cell M1nVSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzNXFdKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>? MnfSV2FPT0WU
NB69 cell M1z4T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITSOJNKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM2ODR5IN88US=> M2\wT3NCVkeHUh?=
NCI-H1693 cell NV7QVVRzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUDxTY5IUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3QTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0PFk2KM7:TR?= NWrWXGI5W0GQR1XS
HSC-3 cell NWnpdHAyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60PVk{OyEQvF2= MV7TRW5ITVJ?
MDA-MB-231 cell NEDv[2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2XKT2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNUW4PVkh|ryP NVnOTY9qW0GQR1XS
HOS cell NFXVW4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwN{i2N{DPxE1? M4nNTnNCVkeHUh?=
BT-549 cell M{PZb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrJcohq[mm2aX;uJI9nKGi3bXHuJGJVNTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|g5PyEQvF2= MYPTRW5ITVJ?
NB17 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnThTY5pcWKrdHnvckBw\iCqdX3hckBPSjF5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFk4PiEQvF2= Mnv3V2FPT0WU
5637 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUK3[ZA6UW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QTZ3MjFOwG0> MYrTRW5ITVJ?
OVCAR-8 cell NV;4bmNYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnf0TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR|NjFOwG0> NEjMXJVUSU6JRWK=
G-402 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M133dWlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk{ODN3IN88US=> MVHTRW5ITVJ?
BB30-HNC cell M{\hPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmXGTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO MmnpV2FPT0WU
HCC1806 cell NF3UfHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MljCTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOEC2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xQDN|OTFOwG0> NWm2VXpJW0GQR1XS
COLO-800 cell M{DvN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLrTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTJ4NDFOwG0> NWmxeHU4W0GQR1XS
FADU cell M4S1Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{i3dGlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|Y2PTdizszN MV3TRW5ITVJ?
NCI-H1651 cell NY[zcVcxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXT5fHFYUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkO5OFA6KM7:TR?= M2iyb3NCVkeHUh?=
AGS cell NFPicmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlvYTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O|EyKM7:TR?= NWPud4ZsW0GQR1XS
CHP-212 cell M1rZS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUnDeHBQUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5|OUSwPUDPxE1? MkTKV2FPT0WU
YAPC cell M3;ofmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJHlCWENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O|EyKM7:TR?= MojWV2FPT0WU
GOTO cell MlzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3nzOGlvcGmkaYTpc44hd2ZiaIXtZY4hT0:WTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFk2PzZizszN MWrTRW5ITVJ?
KYSE-510 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3KTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=> NUXDZ2YxW0GQR1XS
NCI-H2342 cell M4DuT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3rINGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{K3PEDPxE1? MnfmV2FPT0WU
BFTC-905 cell MofrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh|NTFOwG0> NUTDS2s5W0GQR1XS
EW-16 cell NHSwUnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnuXG8xUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyOUOg{txO MWrTRW5ITVJ?
SK-MEL-30 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO Ml;LV2FPT0WU
HLE cell NYSxdIRXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXW2RYFoUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc4PDh7IN88US=> NFvxdXNUSU6JRWK=
T98G cell MmfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?= M13leHNCVkeHUh?=
HUTU-80 cell M17PPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=> MUnTRW5ITVJ?
NOS-1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65OFc3PiEQvF2= NVTxOlNVW0GQR1XS
SW780 cell NYDTOY41T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYHJNW13UW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO MmfqV2FPT0WU
KYSE-180 cell MoHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHTIVJZKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{[1OEDPxE1? NVTMRohJW0GQR1XS
MDA-MB-361 cell M4XRUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M331d2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUi2OFch|ryP MV;TRW5ITVJ?
SNU-C2B cell NWDXT5RlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlLBTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF|ODFOwG0> NUL3dIxWW0GQR1XS
NCI-H661 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV[2bJdEUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwME[5OEDPxE1? NUG2W|FWW0GQR1XS
OE33 cell MlPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nrT2lvcGmkaYTpc44hd2ZiaIXtZY4hV0V|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVQ{QDlizszN MnnTV2FPT0WU
TYK-nu cell NGDZWHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml32TY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ|IN88US=> NIXrUnZUSU6JRWK=
COLO-792 cell NGjFXGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> NX7IfppLW0GQR1XS
HEL cell NIe4O2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMk[3OkDPxE1? MUPTRW5ITVJ?
D-566MG cell NUXaN|lJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvwTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{OzR7MTFOwG0> NF3HUpZUSU6JRWK=
U031 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIH0N|NKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=> MXTTRW5ITVJ?
COR-L23 cell M4fHbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MojSTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0> NIPjVIhUSU6JRWK=
NCI-H2452 cell MlPsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrtd4dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNUKyPFEh|ryP NGDhb4tUSU6JRWK=
BB65-RCC cell MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmT4TY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjR3OTFOwG0> MnP5V2FPT0WU
CAL-33 cell NXHZS2tJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUWxT4ZYUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ3Nk[1JO69VQ>? NFj3fY1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C. November 2006 Phase 1
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products0

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID